Thesis defense Marcelien Callenbach: Fertile Grounds for Outcome-based Managed Entry Agreements? Potential suitability and desirability for highly priced novel therapies

Marcelien's thesis aims to create a more profound insight into the potential suitability and desirability of outcome-based managed entry agreements by integrating uncertainty regarding relative (cost-)effectiveness into reimbursement and payment models for highly priced novel therapies. It provides stakeholders with insights into the circumstances under which these agreements have the potential to be beneficial and when traditional agreements will suffice. Multiple tools/frameworks and case studies are presented to provide a better understanding of the deal of managed entry agreements, ultimately severing the aim of sustainable healthcare systems and creating patient access to novel therapies.

The research is the result of a collaboration between the Division of Pharmacoepidemiology and Clinical Pharmacology of the Utrecht Institute for Pharmaceutical Sciences (UIPS) of Utrecht University and the Dutch Health Care Institute as part of the Research Network HTA.

Please check the Utrecht University PhD agenda, to see the offline and online possibilities to attend Marcelien Callenbach’s PhD defense.